Untitled Document

Pharma & Biotech Team -
Quarterly Update Fourth Quarter 2007

The Pharma & Biotech team at Citigate Dewe Rogerson, the world-leading communications agency, is pleased to provide an update of
team and client activities for the fourth
quarter 2007.


New Clients
	Citigate has been appointed to provide corporate communications consultancy to Affibody, a private Swedish biotech company focused on improving the treatment of cancer through a combination of molecular imaging and individualized targeted treatments.
	Gendux Molecular is focused on the commercialization of targeted molecular therapies to be applied with molecular diagnostic tools to introduce personalized medical products in European and other markets. Citigate will provide corporate communications support to Gendux.
	Photocure ASA is a public Norwegian pharmaceutical company that develops and sells pharmaceuticals and medical devices based on photodynamic technology, targeting key dermatology and oncology markets. Citigate will provide financial and corporate communications consultancy and investor relations activities.
	Gilde Healthcare Partners is a European venture capital firm with more than EUR275 million under management. It primarily invests in emerging therapeutic, diagnostic and medical device companies. Citigate was appointed to provide positioning and communications consultancy around the announcement of Gilde's successful EUR150m fundraising

Team News We are very pleased to announce the appointments of Emma Palmer as a Consultant to and Sylvie Berrebi as a Manager in the Pharma & Biotech Team (see announcement) Emma will help expand the team's activities in financial communications and investor relations, focusing on listed and late-stage private companies in the UK and Europe. Emma spent eight years in investment banking, both as a sell-side analyst at Williams de Broe, Robert Fleming Securities and WestLB Panmure, and latterly as Head of European Healthcare Corporate Finance at ING. She was also Head of Financial Communications and Investor Relations at Northbank Communications and has worked in technology transfer at Cancer Research Campaign Technology (now Cancer Research UK) and as a journalist (at Scrip World Pharmaceutical News). Sylvie has five years' life sciences PR experience from roles at De Facto Communications, Financial Dynamics and Noonan Russo. Sylvie is fluent in French, German and English, and will be supporting the Pharma & Biotech Team's corporate and financial PR and IR offering across Europe.
Portfolio Company News Fund-raisings Medgenics raised GBP3.28 million in its IPO in connection with its admission to the AIM market of the London Stock Exchange Gilde Healthcare Partners raised EUR150 million for its Gilde Healthcare II venture fund Corporate and Business Development Genzyme UK expanded its facilities at the Oxford Business Park to meet demand for its innovative products for the management of chronically debilitating diseases Oxford Genome Sciences entered into a strategic collaboration with Amgen to discover, develop and commercialise novel therapeutic antibodies for the treatment of cancer Photocure announced its plan to de-merge PCI Biotech, its cancer-focused drug delivery subsidiary Product News EMEA accepted for review Gendux's MAA for ADVEXIN as a new gene therapy for inherited cancer Optos received the Technology Innovation of the Year Award at the 2007 techMARK Awards for its retinal-scanning laser technology Clinical Trials Chi-Med received IND and initiates global Phase IIb trials of its lead anti-inflammatory drug candidate, HMPL-004, in ulcerative colitis patients NicOx completes enrollment in second pivotal Phase III study for naproxcinod for treating osteoarthritis Summit plc began Phase I clinical trial in seborrhoea, – a symptom of Parkinson's disease and the primary cause of acne